Viagra IPR Case Goes Another Round

Related entries: Corporate News, General, Risk & Law

I posted recently about the fact that a Beijing Court had supported Pfizer’s battle to protect its patent for Viagra in China (“Viagra’s IPR Battle Just Keeps on Going”). That move was seen as “landmark ruling” for IPR protection in China, but it was never likely to be the end of the story.

Now it is reported (by Reuters) that 12 local firms will appeal against the ruling. The companies are said to include Guangzhou Baiyunshan Medical Technology Development Co. Ltd. and Chongqing Kangerwei Pharmaceutical Co. Ltd., and they are being represented by Beijing Huake Union Patent Office. The report quotes Wang Wei, a lawyer with the firm as saying:

    “I am positive of the result based on the evidence provided by the [State Intellectual Property] office…It might take three to five months for the court to make the decision.”

As I previously noted, the case may not be clear cut, but it is certainly a good thing that it is bringing a lot of focus to the important issue of IPR protection – for foreign and local firms alike. Pfizer has a fight on its hands but, no doubt, their lawyers also have plenty of stamina…

For everybody else, the important lesson to take away from this long-running saga is that intellectual property rights protection in China requires early action and broad application.

China Business Services and our local partners provide a comprehensive range of risk management and IPR protection services. Please contact us to discuss your needs

See news source:

One Response to “Viagra IPR Case Goes Another Round”

  1. Archive » Chinese Pirates Like Chinese Brands Too| China Business Blog Says:

    […] discussion of the hurt felt by foreign companies whose products are pirated in China (e.g. Pfizer, NEC , and Starbucks). Less time is given to consideration of local companies. But all th […]

Leave a Reply

You must be logged in to post a comment.